CAR T cell therapy for kids with CD33 AML that came back
Part of Blood & lymphatic, Cancer clinical trials.
This Phase 1 study tests a type of lab-made immune cell therapy (CAR T cells) made from your T cells to treat AML that has relapsed or not responded, as long as the cancer shows a marker called CD33. The goal is to see if the treatment is safe and can help control AML after it returns or resists standard therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 30 years old or younger (and the first few patients must be 18+).
- Your AML must be CD33-positive on a lab test (flow cytometry).
- Your AML must fit one of these situations: first relapse within 6 months, second-or-later relapse, relapse after 6 months with specific MRD levels, or refractory AML after chemotherapy.
- You must be well enough for treatment (performance score usually at least 50) and have expected survival of at least 8 weeks.
- You must be able to donate/collect cells for manufacturing (apheresis), or have enough already-collected cells.
- Major infections and pregnancy are not allowed, and you must be able to stop certain medicines for specific time windows before enrollment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 study tests a personalized immune-cell treatment (CD33 CAR T cells) for adults with AML that has returned or did not respond to treatment. It aims to see how safe the therapy is and how well it works for AML cells that carry the CD33 marker.
This trial tests a personalized cell therapy called CD33 CAR-T for people whose acute myeloid leukemia has come back or isn't responding to standard treatments. The goal is to see if it's safe and can help eliminate leukemia cells that carry the CD33 protein.
This study tests a new kind of immunotherapy called CAR-T cells that are engineered to find and attack leukemia cells carrying certain markers (CD33, CD123, or CLL-1). The treatment is given in two steps, aiming to kill cancer cells more effectively and possibly with fewer side effects.
This trial tests a new type of immune cell therapy (CAR T cells) for people with acute myeloid leukemia (AML) that has come back or not gone away after treatment. The therapy is designed to find and attack leukemia cells that have a specific marker called CD371.
This trial tests a special immune cell treatment (CAR T cells) that target a protein called FOLR1 found on some AML cells. It is for children aged 6 or younger whose leukemia has come back or not responded to treatment.
This trial tests a new type of cell therapy using natural killer (NK) cells that target a protein called CD33 found on AML cells. The goal is to see if these cells can help treat leukemia that has not responded to standard treatments, and you would receive a stem cell transplant afterward to help your bone marrow recover.
Hear when a new Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.